JP7083206B2 - タンパク質内包高分子ミセル - Google Patents

タンパク質内包高分子ミセル Download PDF

Info

Publication number
JP7083206B2
JP7083206B2 JP2021527739A JP2021527739A JP7083206B2 JP 7083206 B2 JP7083206 B2 JP 7083206B2 JP 2021527739 A JP2021527739 A JP 2021527739A JP 2021527739 A JP2021527739 A JP 2021527739A JP 7083206 B2 JP7083206 B2 JP 7083206B2
Authority
JP
Japan
Prior art keywords
protein
micelles
formula
peg
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021527739A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020262550A1 (https=
Inventor
オラシオ カブラル
アンキ タオ
一紀 五十嵐
拓也 宮崎
ロ ジョージ ファン
ペンウェン チェン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Tokyo NUC
Original Assignee
University of Tokyo NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Tokyo NUC filed Critical University of Tokyo NUC
Publication of JPWO2020262550A1 publication Critical patent/JPWO2020262550A1/ja
Priority to JP2022084284A priority Critical patent/JP2022122912A/ja
Application granted granted Critical
Publication of JP7083206B2 publication Critical patent/JP7083206B2/ja
Priority to JP2025169836A priority patent/JP2026010025A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G81/00—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/04—Peptides being immobilised on, or in, an organic carrier entrapped within the carrier, e.g. gel, hollow fibre
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10—Alpha-amino-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/40—Polyamides containing oxygen in the form of ether groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Nanotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Variable-Direction Aerials And Aerial Arrays (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Polyamides (AREA)
JP2021527739A 2019-06-28 2020-06-25 タンパク質内包高分子ミセル Active JP7083206B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022084284A JP2022122912A (ja) 2019-06-28 2022-05-24 タンパク質内包高分子ミセル
JP2025169836A JP2026010025A (ja) 2019-06-28 2025-10-08 タンパク質内包高分子ミセル

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962868040P 2019-06-28 2019-06-28
US62/868,040 2019-06-28
PCT/JP2020/025086 WO2020262550A1 (ja) 2019-06-28 2020-06-25 タンパク質内包高分子ミセル

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022084284A Division JP2022122912A (ja) 2019-06-28 2022-05-24 タンパク質内包高分子ミセル

Publications (2)

Publication Number Publication Date
JPWO2020262550A1 JPWO2020262550A1 (https=) 2020-12-30
JP7083206B2 true JP7083206B2 (ja) 2022-06-10

Family

ID=74060587

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021527739A Active JP7083206B2 (ja) 2019-06-28 2020-06-25 タンパク質内包高分子ミセル
JP2022084284A Withdrawn JP2022122912A (ja) 2019-06-28 2022-05-24 タンパク質内包高分子ミセル
JP2025169836A Pending JP2026010025A (ja) 2019-06-28 2025-10-08 タンパク質内包高分子ミセル

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022084284A Withdrawn JP2022122912A (ja) 2019-06-28 2022-05-24 タンパク質内包高分子ミセル
JP2025169836A Pending JP2026010025A (ja) 2019-06-28 2025-10-08 タンパク質内包高分子ミセル

Country Status (8)

Country Link
US (2) US20220249689A1 (https=)
EP (1) EP3992229A4 (https=)
JP (3) JP7083206B2 (https=)
CN (2) CN117024749A (https=)
AU (1) AU2020305308B2 (https=)
CA (1) CA3144358A1 (https=)
IL (2) IL289188B2 (https=)
WO (1) WO2020262550A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022122912A (ja) * 2019-06-28 2022-08-23 国立大学法人 東京大学 タンパク質内包高分子ミセル

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023102362A (ja) * 2022-01-12 2023-07-25 国立大学法人 東京大学 サイトカイン内包高分子ミセル
EP4536679A1 (en) * 2022-06-11 2025-04-16 The University Of Tokyo Nucleic acid closing polymeric micelle
JP2024130631A (ja) * 2023-03-15 2024-09-30 国立大学法人 東京大学 ｐＨ応答性タンパク質送達用担体
JP2024130632A (ja) * 2023-03-15 2024-09-30 国立大学法人 東京大学 タンパク質送達用ｐＨ応答性担体
WO2025229172A1 (en) 2024-05-03 2025-11-06 Institut National de la Santé et de la Recherche Médicale Live cell encapsulation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040162235A1 (en) 2003-02-18 2004-08-19 Trubetskoy Vladimir S. Delivery of siRNA to cells using polyampholytes
JP2005529931A (ja) 2002-05-24 2005-10-06 マイラス コーポレイション 膜相互作用の可逆的改質

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2690276B2 (ja) 1995-01-10 1997-12-10 科学技術振興事業団 静電結合型高分子ミセル薬物担体とその薬剤
US6509313B1 (en) 1996-02-28 2003-01-21 Cornell Research Foundation, Inc. Stimulation of immune response with low doses of cytokines
US6383811B2 (en) 1997-12-30 2002-05-07 Mirus Corporation Polyampholytes for delivering polyions to a cell
US8541548B2 (en) 1999-06-07 2013-09-24 Arrowhead Madison Inc. Compounds and methods for reversible modification of biologically active molecules
US8211468B2 (en) 1999-06-07 2012-07-03 Arrowhead Madison Inc. Endosomolytic polymers
US6511676B1 (en) 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
AU2001275423B2 (en) 2000-06-09 2007-01-11 Regulon, Inc. Encapsulation of polynucleotides and drugs into targeted liposomes
AU2001296800A1 (en) 2000-10-06 2002-04-15 Johns Hopkins University Systemic delivery of compounds through non-invasive bladder administration
KR20100039911A (ko) 2001-10-13 2010-04-16 아스테리온 리미티드 폴리펩타이드들을 포함하는 글리코실포스파티딜이노시톨
US20030147958A1 (en) 2002-01-29 2003-08-07 Cheol-Hee Ahn Biodegradable multi-block copolymers of poly(amino acid)s and poly(ethylene glycol) for the delivery of bioactive agents
CA2679185A1 (en) 2007-02-28 2008-09-04 Advinus Therapeutics Private Limited 2,2,2-tri-substituted acetamide derivatives as glucokinase activators, their process and pharmaceutical application
RU2526904C2 (ru) 2007-05-11 2014-08-27 Дзе Борд Оф Риджентс Оф Дзе Юнивёрсити Оф Небраска Композиции для доставки белков и методы их применения
KR101564796B1 (ko) * 2008-03-10 2015-10-30 고쿠리츠다이가쿠호우진 도쿄다이가쿠 비하전성 친수성 블록 및 측사슬의 일부에 소수성 기가 도입된 카티온성 폴리아미노산 블록을 포함하여 이루어지는 공중합체, 그 사용
JP5472288B2 (ja) * 2009-03-17 2014-04-16 国立大学法人 東京大学 タンパク質の電荷調節剤、及びタンパク質内包高分子ミセル複合体
CN102971002B (zh) 2010-07-09 2019-04-05 国立大学法人东京大学 核酸递送用组合物及载体组合物、使用其的药物组合物以及核酸递送方法
US9481661B2 (en) 2011-06-17 2016-11-01 Arrowhead Madison, Inc. Disubstituted maleic anhydrides with altered kinetics of ring closure
EP3284474B1 (en) 2015-04-16 2019-12-25 University of Tsukuba Polyion complex of poly(l-arginine) segment-containing block copolymer and polyanionic polymer
WO2017078883A1 (en) 2015-11-06 2017-05-11 3M Innovative Properties Company Redox polymerizable composition with photolabile transition metal complexes
EP3495406A4 (en) * 2016-08-02 2020-04-01 Nippon Kayaku Kabushiki Kaisha ACTIVE TARGETING TYPE POLYMER DERIVATIVE, COMPOSITION CONTAINING SAID POLYMER DERIVATIVE, AND USES OF SAID POLYMER DERIVATIVE AND COMPOSITION THEREOF
JP7285220B2 (ja) 2017-05-18 2023-06-01 モデルナティエックス インコーポレイテッド 連結したインターロイキン－１２（ｉｌ１２）ポリペプチドをコードするポリヌクレオチドを含む脂質ナノ粒子
EP3788094A2 (en) 2018-04-27 2021-03-10 Genedit Inc. Cationic polymer and use for biomolecule delivery
SG11202110810WA (en) 2019-03-29 2021-10-28 Torque Therapeutics Inc Immunotherapeutic compositions and use thereof
WO2020261227A1 (en) 2019-06-26 2020-12-30 Biorchestra Co., Ltd. Micellar nanoparticles and uses thereof
CN117024749A (zh) 2019-06-28 2023-11-10 国立大学法人东京大学 蛋白质内包高分子胶束
TW202214290A (zh) 2020-04-22 2022-04-16 瑞士商諾華公司 異源二聚體人介白素－１５（ｈｅｔｉｌ－１５）之藥物組成物及藥物產品
AR122446A1 (es) 2020-04-29 2022-09-14 Medimmune Llc Composiciones y métodos para suministrar agentes farmacéuticamente activos
US20240252696A1 (en) 2020-05-27 2024-08-01 Georgetown University Targeting the cholecystokinin-b receptor for imaging and early detection of pancreatic cancer and pre-cancerous lesions
US20230381112A1 (en) 2020-09-22 2023-11-30 Vaccitech North America, Inc. Compositions and Methods of Manufacturing Amphiphilic Block Copolymers that Form Nanoparticles in Situ
JP2024512761A (ja) 2021-03-29 2024-03-19 オーディー セラピューティクス リミテッド タンパク質－高分子コンジュゲートおよびその使用方法
FR3122573B1 (fr) 2021-05-10 2024-03-29 Hydro Fill Tech Compositions de conjugués poly-lysine et de micelles et/ou de copolymères de poly-lysine
WO2023116702A1 (zh) 2021-12-21 2023-06-29 华南理工大学 pH敏感的破膜聚肽及其应用
JP2023102362A (ja) 2022-01-12 2023-07-25 国立大学法人 東京大学 サイトカイン内包高分子ミセル
EP4536679A1 (en) 2022-06-11 2025-04-16 The University Of Tokyo Nucleic acid closing polymeric micelle
CN116284759B (zh) 2022-11-29 2025-02-11 深圳先进技术研究院 一种聚多肽基因载体及其制备方法和应用
CN116139104A (zh) 2022-11-29 2023-05-23 深圳先进技术研究院 一种靶向性仿生聚多肽纳米递送载体、纳米核酸递送系统及其制备方法和应用
JP2024130632A (ja) 2023-03-15 2024-09-30 国立大学法人 東京大学 タンパク質送達用ｐＨ応答性担体
JP2024130631A (ja) 2023-03-15 2024-09-30 国立大学法人 東京大学 ｐＨ応答性タンパク質送達用担体
CN116270541B (zh) 2023-03-28 2025-04-29 中山大学 抗铜绿假单胞菌感染的纳米粒及制备方法和肺部吸入制剂

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005529931A (ja) 2002-05-24 2005-10-06 マイラス コーポレイション 膜相互作用の可逆的改質
US20040162235A1 (en) 2003-02-18 2004-08-19 Trubetskoy Vladimir S. Delivery of siRNA to cells using polyampholytes

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Bioconjugate Chemistry，2003年，Vol.14，p.51-57
Biomacromolecules，2016年，Vol.17，p.246-255
Current Opinion in Chemical Biology，2015年，Vol.28，p.181-193
International Journal of Nanomedicine，2018年，Vol.13，p.7229-7249

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022122912A (ja) * 2019-06-28 2022-08-23 国立大学法人 東京大学 タンパク質内包高分子ミセル

Also Published As

Publication number Publication date
IL289188B1 (en) 2025-01-01
JPWO2020262550A1 (https=) 2020-12-30
EP3992229A1 (en) 2022-05-04
CN114080412A (zh) 2022-02-22
IL289188B2 (en) 2025-05-01
US20250242047A1 (en) 2025-07-31
EP3992229A4 (en) 2023-05-31
CA3144358A1 (en) 2020-12-30
US20220249689A1 (en) 2022-08-11
CN117024749A (zh) 2023-11-10
WO2020262550A1 (ja) 2020-12-30
JP2026010025A (ja) 2026-01-21
AU2020305308A1 (en) 2022-01-27
IL289188A (en) 2022-02-01
JP2022122912A (ja) 2022-08-23
CN114080412B (zh) 2023-08-25
IL317420A (en) 2025-02-01
AU2020305308B2 (en) 2026-04-09
US12611465B2 (en) 2026-04-28

Similar Documents

Publication Publication Date Title
JP7083206B2 (ja) タンパク質内包高分子ミセル
Tao et al. Polymeric micelles loading proteins through concurrent ion complexation and pH‐cleavable covalent bonding for in vivo delivery
JP5472288B2 (ja) タンパク質の電荷調節剤、及びタンパク質内包高分子ミセル複合体
US20250177545A1 (en) Cytokine-encapsulating polymeric micelle
CN111973556B (zh) 载小分子药聚合物囊泡及其制备方法与应用
CN110229323A (zh) 还原敏感可逆交联的具有不对称膜结构的聚合物囊泡及其在制备治疗肝癌药物中的应用
US20030185798A1 (en) Biocompatible polymers including peptide spacer
WO2020241819A1 (ja) 複合体、医薬、癌治療剤、キット及び結合体
JP6292632B2 (ja) ポリカチオン性トリブロックコポリマーとポリアニオン性ポリマーと生理活性ペプチドを含む組成物
JP2024512505A (ja) 免疫細胞への核酸の効率的な細胞内送達のための樹状ペプチド結合ポリマー
WO2024190929A1 (ja) タンパク質送達用ｐＨ応答性担体
Du et al. Azo-capped polysarcosine-b-polylysine as polypeptide gene vector: a new strategy to improve stability and easy optimization via host–guest interaction
WO2022041017A1 (zh) 载小分子药聚合物囊泡及其制备方法与应用
CN119751855B (zh) 一种多价态可离子化脂质-多肽及其制备方法与应用
Cui et al. Unlocking intracellular targets: Smart multistage-responsive polyionic vesicular platforms for advancing protein-based therapy
CN120329466A (zh) 一种抗蛋白粘附的细胞亲和性两性离子聚合物及其应用
CN111704705A (zh) 一种嵌段聚合物及其制备方法以及一种载药囊泡和靶向载药囊泡
CN118684894A (zh) 一种tuftsin肽修饰的二硫键交联的聚乙烯亚胺聚合物及其制备方法和应用
Ibrahimova Development of polypeptide-based multifunctional nano-assemblies for a theranostic approach
Lu Zwitterionic Polymer For Drug Delivery Applications
Vusala Development of Polypeptide-Based Multifunctional Nano-Assemblies for a Theranostic Approach

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220113

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220119

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20220119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220308

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220405

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220426

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220524

R150 Certificate of patent or registration of utility model

Ref document number: 7083206

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250